MannKind Fights On With Its Diabetes Game-Changer Afrezza

[Northerner]

MannKind Corporation (MNKD) is a biotechnology company with a market capitalisation of ~$430 million and current share price of $2.57. MannKind's lead product in development is Afrezza, an inhalable insulin used in the treatment of Type 1 and Type 2 Diabetes. MannKind has had some significant setbacks over the last couple of years. The company's share price was $10.48 in March 2010 when it received its first Complete Response Letter from the FDA for Afrezza. Consequently the share price plunged to $4.95 before climbing back to a peak of $9.64 in January 2011 when it then received a second Complete Response Letter. Following this MannKind cut 47% of its staff and put a hold on development of its other pipeline products to focus on Afrezza.

http://seekingalpha.com/article/704841-mannkind-fights-on-with-its-diabetes-game-changer-afrezza